Profile data is unavailable for this security.
About the company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-35.19m
- Incorporated1998
- Employees32.00
- LocationElicio Therapeutics Inc451 D Street, 5Th FloorBOSTON 02459United StatesUSA
- Phone+1 (857) 209-0050
- Fax+1 (302) 655-5049
- Websitehttps://elicio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yubo International Biotech Ltd | 604.68k | -1.20m | 95.86m | 18.00 | -- | -- | -- | 158.52 | -0.01 | -0.01 | 0.005 | -0.0154 | 0.3012 | 0.6912 | 9.19 | 33,593.33 | -59.52 | -- | -- | -- | 69.32 | -- | -197.64 | -- | 0.1504 | -3,143.97 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -116.19m | 96.58m | 65.00 | -- | 0.9048 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Clearside Biomedical Inc | 8.45m | -34.97m | 97.90m | 30.00 | -- | -- | -- | 11.58 | -0.543 | -0.543 | 0.1321 | -0.2919 | 0.1993 | -- | -- | 281,733.30 | -82.44 | -63.57 | -94.63 | -81.77 | 93.08 | -- | -413.72 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 98.08m | 81.00 | -- | 1.01 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Genelux Corp | 8.00k | -25.78m | 98.54m | 23.00 | -- | 6.43 | -- | 12,317.26 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -53.37m | 100.64m | 54.00 | -- | 1.42 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -94.30m | 100.78m | 20.00 | -- | 1.40 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Assertio Holdings Inc | 142.05m | -332.97m | 101.78m | 53.00 | -- | 0.7567 | -- | 0.7165 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Angion Biomedica Corp | 0.00 | -35.19m | 102.83m | 32.00 | -- | 8.49 | -- | -- | -8.81 | -8.81 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -88.05 | -105.91 | -110.32 | -331.69 | -- | -- | -- | -712.81 | -- | -700.88 | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Hongchang International Co Ltd | 2.67m | -365.80k | 103.82m | 8.00 | -- | 2.62 | -- | 38.93 | -0.0006 | -0.0006 | 0.0055 | 0.0763 | 0.0993 | -- | 175.86 | -- | -1.36 | -7.98 | -1.42 | -10.94 | 3.03 | 11.47 | -13.72 | -64.88 | 5.86 | -- | 0.2263 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Beyondspring Inc | 1.75m | -21.03m | 104.40m | 35.00 | -- | -- | -- | 59.62 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 104.65m | 29.00 | 1.38 | 1.41 | -- | 0.7455 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Rezolute Inc | 0.00 | -58.21m | 105.94m | 51.00 | -- | 1.50 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -65.10m | 108.03m | 63.00 | -- | 0.5080 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Data as of May 17 2024. Currency figures normalised to Elicio Therapeutics Inc's reporting currency: US Dollar USD
4.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 215.69k | 2.11% |
| CM Management LLCas of 31 Mar 2024 | 75.00k | 0.73% |
| Geode Capital Management LLCas of 31 Mar 2024 | 47.70k | 0.47% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 17.60k | 0.17% |
| Meyer Handelman Co. LLCas of 31 Mar 2024 | 13.90k | 0.14% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 12.50k | 0.12% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 11.76k | 0.12% |
| Welcome Asset Management SGIIC SAas of 31 Dec 2023 | 9.99k | 0.10% |
| CIBC Private Wealth Advisors, Inc.as of 31 Mar 2024 | 7.00k | 0.07% |
| Steward Partners Investment Advisory LLCas of 31 Mar 2024 | 1.55k | 0.02% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
